TNFRSF17 and plasma cell myeloma: To test the utility of NSG+hIL6 mice for modeling MM therapies, we treated myeloma-engrafted NSG+hIL6 mice with either human BCMA-directed CAR T cells (BCMA-CART cells) (28, 29) or bortezomib.